This study increased our understanding of CXCR2 antagonists and revealed that early administration of CXCR2 antagonists with DNase I may become a potential therapeutic strategy for preventing HCC lung metastasis, especially in SPP1-positive HCC patients. The gene discussed is CXCR2; the disease is hepatocellular carcinoma.